{"entity":{"id":"nct05990803","kind":"trial","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies","aka":[],"tldr":"A phase 2 trial of Izalontamab brengitecan in cervical cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies is a phase 2 interventional study registered as NCT05990803 by Sichuan Baili Pharmaceutical Co., Ltd., with 130 participants planned, started 2023-11-06 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1, SI-B003. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05990803","url":"https://clinicaltrials.gov/study/NCT05990803"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cervical","recurrent-metastatic-cervical-cancer"],"sections":[],"technologies":["adc","bispecific-adc"],"targets":[],"drugs":["izalontamab-brengitecan"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05990803","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 Monotherapy, SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT05990803","source":"https://clinicaltrials.gov/study/NCT05990803","fetchedAt":"2026-10-07T16:54:05.353Z","studySha256":"ca1a8b9e726dc593f9720ba5ead5b6f7b22ad766a2886c2b228444a0f9438d83","overallStatus":"RECRUITING","lastUpdatePosted":"2025-09-26","leadSponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":130,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2023-11-06","startedType":"actual","enrolled":130,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05990803/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"}],"drug":[{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}